Reneuron Gp (OTCMKTS:RNUGF) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued on Saturday.

According to Zacks, “ReNeuron Group plc is involved in the development of cell-based therapies. Its therapeutic candidate is CTX stem cell therapy for the treatment of patients left disabled by the effects of a stroke which are in clinical development phase. ReNeuron Group plc is headquartered in Pencoed, the United Kingdom. “

Reneuron Gp (OTCMKTS RNUGF) opened at $0.02 on Friday. Reneuron Gp has a 52 week low of $0.02 and a 52 week high of $0.05.

ILLEGAL ACTIVITY WARNING: “Reneuron Gp (RNUGF) Stock Rating Lowered by Zacks Investment Research” was first published by American Banking News and is owned by of American Banking News. If you are accessing this news story on another site, it was illegally copied and reposted in violation of international trademark & copyright legislation. The correct version of this news story can be viewed at https://www.americanbankingnews.com/2018/01/06/reneuron-gp-rnugf-stock-rating-lowered-by-zacks-investment-research.html.

About Reneuron Gp

ReNeuron Group plc develops and sells cell-based therapies in the United Kingdom. The company’s lead therapeutic candidate is CTX stem cell therapy, which has been completed Phase III clinical trial for the treatment of patients left disabled by the effects of a stroke, as well as that has been completed Phase I clinical trial to treat critical limb ischaemia, a side effect of diabetes.

Get a free copy of the Zacks research report on Reneuron Gp (RNUGF)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Reneuron Gp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reneuron Gp and related companies with MarketBeat.com's FREE daily email newsletter.